Table 9– Relationship of incremental shuttle walk test (ISWT) to clinical outcomes
First author [ref.]DiagnosisMean±sd age yearsDisease severityStudy designOutcomesResult
Emtner [220]COPD post exacerbation65±9.5SevereProspective cohortISWT and hospitalisationMean±sd ISWT: hospitalisation at 12 months (n=9) 174±124 m, no hospitalisation at 12 months (n=12) 358±94 m, p=0.001 between groups; hazard risk ratio of hospitalisation at 12 months was 0.80 (95% CI 0.67–0.97) per 10 m
Ketchell [221]CF24End-stageRetrospectiveISWT and survivalNo significant association between distance on the ISWT and survival
Ringbaek [222]COPD68.0±9.3SevereCohortISWT and survivalHazard ratio of mortality in patients who achieved <170 m versus patients who achieved ≥170 m was 2.83 (95% CI 2.05–3.90) in univariate analysis and 2.84 (95% CI 2.05–3.93) in multivariate analysis, p<0.05; the two highest quartiles of ISWT distance were equal in the regression model, suggesting the association is not linear
Williams [223]COPD68.9±9.0Moderate to severeObservational, cohortIncorporating the ISWT into the BODE score (FEV1 % predicted, MRC and BMI), age, pack-years, GOLD stage, FVC and survivalBMI, MRC, ISWT, age and pack-years significantly associated with survival; hazard ratio for death per 1-point increase on i-BODE score was 1.27 (95% CI 1.18–1.36), p<0.001
  • COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; BODE: body mass index, airflow obstruction, dyspnoea and exercise capacity; FEV1: forced expiratory volume in 1 s; MRC: Medical Research Council dyspnoea score; BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FVC: forced vital capacity; i-BODE: BODE index incorporating ISWT.